ADOCIA

ADOCIA est membre de Lyonbiopôle

General information

115 avenue Lacassagne

69003 LYON

Incorporated in: 2005/12/22

Number of employees: 125


More information

 

Main activity

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s portfolio of injectable treatments for diabetes, featuring five clinical-stage products and three preclinical products, is among the largest and most differentiated of the industry.


Funding

Private funding obtained: 1.6 million euros raised at the company's inception. 12 million euros raised in November 2007. 17 million euros raised in January 2009. 14 million euros raised in January 2010. 32 million euros raised through a private placement in March 2015

Public funding obtained: Oseo: 2.2 M€ granted in 2007 (Osteoporosis). FEDER: 0,4 M€ granted in 2010 (Insulin).  FEDER: 0,8 M€ granted in 2012 (Insulin).  Oseo: 0,8 M€ granted in 2012 (Insulin project). 

Stock exchange listing:  NYSE-Euronext -Paris - 2012. 27.4 million euros raised.

Segmentation
Activities
Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine


Application market
Endocrinology - Others - Metabolic Diseases


Activities
Therapeutics, Pharma or Biotech


Technologies
Others

En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies pour vous proposer des services et offres adaptés à vos centres d'intérêt. En savoir plus... Fermer